Durvalumab Plus Tarlatamab Improves Overall Survival in First-Line Extensive-Stage Small Cell Lung Cancer
Elizabeth Mittendorf: Grateful to Represent ASCO at the KSMO Annual Meeting in Seoul
VIRO 2026 – Global Voices in Renal Oncology
Down Syndrome and Leukemia: How an Extra Copy of Chromosome 21 Changes Cancer Risk
Arlocabtagene Autoleucel Meets Primary Endpoint in Phase 2 QUINTESSENTIAL Trial for Multiple Myeloma
Pyxis Oncology Appoints Thomas Civik as CEO and Chairman of the Board
Shaalan Beg: When AI Enters the Clinic
Cureety Acquires Reimagine Care, Assembling a Transatlantic Platform for Cancer Care Between Visits
